scholarly journals Hyperactivated Signaling Pathways of Chemokine RANTES/CCL5 in Osteopathies of Jawbone in Breast Cancer Patients–-Case Report and Research

2014 ◽  
Vol 8 ◽  
pp. BCBCR.S15119 ◽  
Author(s):  
Johann Lechner ◽  
Volker Von Baehr
Keyword(s):  
Breast Cancer ◽  
Case Report ◽  
Immune System ◽  
Signaling Pathways ◽  
Cancer Patients ◽  
The Other ◽  
Breast Cancer Patients ◽  
Immune Mediators ◽  
Healthy Control ◽  
Rantes Production

Background Hollow spaces in the jawbone have been defined as fatty degenerative osteonecrosis of jawbone (FDOJ) and have been linked with a dysregulated immune system. Little is known about the underlying relationship. Objectives Samples of FDOJ were analyzed to assess expression of cytokines which can play a role in the pathogenesis of breast cancer (MaCa). Material and Methods Samples of FDOJ extracted from 23 patients with MaCa and 19 healthy control jawbone samples were analyzed for 7 immune messengers. Results RANTES was found to be highly overexpressed in disease samples. No change was observed in expression levels of the other immune mediators. Discussion This data provides a compelling confirmation that FDOJ produces high levels of RANTES, a cytokine implicated in MaCa and metastasis. Levels detected in FDOJ are five-fold higher than that previously reported for MaCa tissue suggesting its role as a cytokine source in MaCa. Conclusion We thus hypothesize that FDOJ may serve as an expeditor of MaCa progression, through RANTES production.

scholarly journals Alterations of Signaling Pathways Related to the Immune System in Breast Cancer: New Perspectives in Patient Management

2018 ◽  
Vol 19 (9) ◽  
pp. 2733 ◽  
Author(s):  
Andrea Nicolini ◽  
Paola Ferrari ◽  
Lucrezia Diodati ◽  
Angelo Carpi
Keyword(s):  
Breast Cancer ◽  
Immune System ◽  
Signaling Pathways ◽  
Cancer Patients ◽  
Immune Evasion ◽  
Experimental Studies ◽  
New Drugs ◽  
Breast Cancer Patients ◽  
Tumor Initiating Cells ◽  
Immune Manipulation

In recent years, immune manipulation for cancer treatment, including breast cancer, has been increasingly gaining consent, and many attempts have been made, mainly by either strengthening the immune response (IR) or by inhibiting immune evasion. Therefore, elucidating the related mechanisms is of importance due to the potential to improve the management of cancer patients by immunotherapy. This review article summarized some recent experimental studies, which have discovered novel alterations of signaling pathways related to the immune system in breast cancer. These altered signaling pathways have been grouped according to the general biological mechanism involved: tumor-initiating cells (TICs), cancer stem cells (CSCs), immune evasion, tumor growth and progression, prediction of clinical outcome and prediction of response, or resistance to chemotherapy. These altered pathways related to the immune system open clinical opportunities for the prognosis or treatment of patients. Many of these pathways are related to the origin of breast cancer and immune evasion. We recommended development of new drugs which act on these molecular pathways, and the designing of clinical trials to be carried out mainly in breast cancer patients who required adjuvant treatment.

Influence of physical activity on the immune system in breast cancer patients during chemotherapy

2018 ◽  
Vol 144 (3) ◽  
pp. 579-586 ◽  
Author(s):  
Thorsten Schmidt ◽  
Walter Jonat ◽  
Daniela Wesch ◽  
Hans-Heinrich Oberg ◽  
Sabine Adam-Klages ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Physical Activity ◽  
Immune System ◽  
Cancer Patients ◽  
Breast Cancer Patients

Multidimensional visualization for the immune system state presentation in breast cancer patients

2015 ◽  
Author(s):  
M. Stakheyeva ◽  
D. Eidenzon ◽  
N. Cherdyntseva ◽  
E. Slonimskaya ◽  
E. Cherdyntsev
Keyword(s):  
Breast Cancer ◽  
Immune System ◽  
Cancer Patients ◽  
System State ◽  
Breast Cancer Patients ◽  
Multidimensional Visualization

Compliance with consensus recommendations for systemic therapy, breast cancer intrinsic subtype, and clinical outcome.

2011 ◽  
Vol 29 (27_suppl) ◽  
pp. 262-262
Author(s):  
S. Takayama ◽  
J. Matsui ◽  
N. Ando
Keyword(s):  
Breast Cancer ◽  
Clinical Outcome ◽  
Cancer Patients ◽  
The Other ◽  
Breast Cancer Patients ◽  
Luminal A ◽  
Consensus Recommendations ◽  
Time To Recurrence ◽  
Kaplan Meier

262 Background: Consensus recommendations for breast cancer are come into wide use, and we believe clinical guidelines leads our patients to improved outcome. Recently, gene profiling can be available, and immunohistochemical surrogates for molecular subtyping can provide much of prognostic and predictive factors. We investigated the relationship between compliance with consensus recommendations and clinical outcome of each subtype on the hypothesis that conformity with consensus recommendations is associated with increased survival among all intrinsic subtypes. Methods: We investigated breast cancer patients operated in our hospital from 2002 to 2004. DCIS, Stage 4 and male breast cancer were excluded. Patients were divided into luminal A (ER+ and/or PgR+, HER2-, low nuclear grade (NG)), luminal B (ER+ and/or PgR+, HER2-, high NG), luminal-HER2 (ER+ and/or PgR+, HER2+), HER2 (ER-, PgR-, HER2+) and triple negative (TN), (ER-, PgR-, HER2-). All patients were divided into compliance group or non-compliance group according to their conformity with consensus recommendations. Kaplan-Meier analysis was used in statistical studies. Results: 121 breast cancer patients were eligible and investigated in this study. Median follow-up period was 6.7 years. Fifteen relapse cases (12.4%) were identified. Among luminal A patients, compliance group was significantly associated with better recurrence free survival compared with non-compliance group with Kaplan-Meier analysis (p<0.001). In contrast, there was no difference between compliance group and non-compliance group among the other subtypes. Median time to recurrence (4.2 year) in non-compliance group among luminal A was apparently longer than that (1.7 year) in compliance group among the other subtypes. Conclusions: Compliance group was significantly associated with better clinical outcome compared with non-compliance group among luminal A. This study suggests that cautious follow-up is required against non-compliance patients among luminal A, because time to recurrence of them was longer than that of both compliance and non-compliance subgroups among the other subtypes.

The effect of diet changes on the immune system of breast cancer patients

1993 ◽  
Vol 93 (9) ◽  
pp. A29 ◽  
Author(s):  
B.K Garritson ◽  
A Nikaein ◽  
M.A Gorman ◽  
G.N Peters ◽  
C King ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Immune System ◽  
Cancer Patients ◽  
Breast Cancer Patients

scholarly journals Role of Metastasis in Hypertabastic Survival Analysis of Breast Cancer: Interaction with Clinical and Gene Expression Variables

2012 ◽  
Vol 5 ◽  
pp. CGM.S8821 ◽  
Author(s):  
Mohammad A. Tabatabai ◽  
Wayne M. Eby ◽  
Nadim Nimeh ◽  
Karan P. Singh
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Estrogen Receptor ◽  
Cancer Patients ◽  
Estrogen Receptor Status ◽  
The Other ◽  
Primary Concern ◽  
Breast Cancer Patients ◽  
Receptor Status

This paper analyzes the survival of breast cancer patients, exploring the role of a metastasis variable in combination with clinical and gene expression variables. We use the hypertabastic model in a detailed analysis of 295 breast cancer patients from the Netherlands Cancer Institute given in. 1 In comparison to Cox regression the increase in accuracy is complemented by the ability to analyze the time course of the disease progression using the explicitly described hazard and survival curves. We also demonstrate the ability to compute deciles for survival and probability of survival to a given time. Our primary concern in this article is the introduction of a variable representing the existence of metastasis and the effects on the other clinical and gene expression variables. In addition to making a quantitative assessment of the impact of metastasis on the prospects for survival, we are able to look at its interactions with the other prognostic variables. The estrogen receptor status increase in importance, while the significance of the gene expression variables used in the combined model diminishes. When considering only the subgroup of patients who experienced metastasis, the covariates in the model are only the clinical variables for estrogen receptor status and tumor grade.

FEATURES

2018 ◽  
Vol 22 (06) ◽  
pp. 16-39
Keyword(s):  
Breast Cancer ◽  
Artificial Intelligence ◽  
Cancer Research ◽  
Immune System ◽  
Cancer Patients ◽  
Molecular Diagnostics ◽  
Multidisciplinary Team ◽  
Clinical Utility ◽  
Breast Cancer Patients ◽  
Exercise Regime

Artificial Intelligence: saving lives and securing the future. The best pill for cancer patients: An exercise regime. Across the divide: Multidisciplinary team to achieve better outcomes for breast cancer patients. The state of cancer research in Asia. Clinical utility of and access to cancer molecular diagnostics in Asia. Reprogramming the immune system against cancer.

scholarly journals Paradoxical Association of Postoperative Plasma Sphingosine-1-Phosphate with Breast Cancer Aggressiveness and Chemotherapy

2017 ◽  
Vol 2017 ◽  
pp. 1-7 ◽  
Author(s):  
Rajesh Ramanathan ◽  
Ali Raza ◽  
Jamie Sturgill ◽  
Debra Lyon ◽  
Jessica Young ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Therapy ◽  
Cancer Patients ◽  
Cancer Progression ◽  
Regulatory Function ◽  
Lipid Mediator ◽  
Breast Cancer Patients ◽  
Cancer Aggressiveness ◽  
Sphingosine 1 Phosphate ◽  
Healthy Control

Sphingosine-1-phosphate (S1P) is a bioactive lipid mediator that has been shown to serve an important regulatory function in breast cancer progression. This study analyzes plasma S1P levels in breast cancer patients undergoing adjuvant therapy as compared to healthy control volunteers. 452 plasma S1P samples among 158 breast cancer patients, along with 20 healthy control volunteers, were analyzed. Mean S1P levels did not significantly differ between cancer patients and controls. Smoking was associated with higher S1P levels in cancer patients. Baseline S1P levels had weak inverse correlation with levels of the inflammatory mediator interleukin- (IL-) 17 and CCL-2 and positive correlation with tumor necrosis factor alpha (TNF-α). Midpoint S1P levels during adjuvant therapy were lower than baseline, with near return to baseline after completion, indicating a relationship between chemotherapy and circulating S1P. While stage of disease did not correlate with plasma S1P levels, they were lower among patients with Her2-enriched and triple-negative breast cancer as compared to luminal-type breast cancer. Plasma S1P levels are paradoxically suppressed in aggressive breast cancer and during adjuvant chemotherapy, which raises the possibility that postoperative plasma S1P levels do not reflect S1P secretion from resected breast cancer.

Sign in / Sign up

Export Citation Format

Share Document